Sponsor Dossier
Novo Nordisk Pharmaceuticals
Sponsor Dossier for Novo Nordisk Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTRAPID
- Brand: ALHEMO
- Brand: AWIQLI
- Brand: ESPEROCT
- Brand: ESTROFEM
- Brand: FIASP
- Brand: GLUCAGEN
- Brand: KLIOGEST
- Device (sponsor): Cartridge-accepting autoinjector, mechanical
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
- Device (sponsor): Needle, injector, medication/vaccine
- Device (sponsor): Injector, medication/vaccine, needle
- Device (sponsor): Needle guard
- Device (sponsor): Needle introducer
- Device (sponsor): Injector, medication/vaccine, needle
About
Novo Nordisk Pharmaceuticals is an Australian Private Company with ABN 40002879996, registered in New South Wales. The entity is active.
Portfolio
Novo Nordisk Pharmaceuticals holds 31 brands on the ARTG, of which 29 are indexable. The portfolio includes 23 brands with Product Information on file, 7 PBS-listed brands, 9 brands with PBAC outcomes, and 13 brands with AusPARs. Notable brands include ACTRAPID, ALHEMO, AWIQLI, ESPEROCT, ESTROFEM, FIASP, GLUCAGEN, KLIOGEST, KLIOVANCE, LEVEMIR, MIXTARD, and NORDITROPIN FLEXPRO.
Therapeutic focus —
Endocrinology: 17 brands — Haematology: 5 brands — Women's Health: 4 brands — Cardiology: 3 brands — Infectious Disease: 1 brand — Reproductive Health: 1 brand
PBS footprint
Seven brands in the portfolio hold at least one PBS-listed item, with the latest schedule date of 2026-05-01.
Regulatory activity
The most recent PBAC outcome for Novo Nordisk Pharmaceuticals is dated 2025-07-01, with 9 brands carrying PBAC outcomes on record. The latest AusPAR is dated 2023-07-03, with 13 brands holding AusPARs on record.